Literature DB >> 16644300

Homocysteine enhances apoptosis in human bone marrow stromal cells.

Duk Jae Kim1, Jung-Min Koh, Oksun Lee, Na Jung Kim, Young-Sun Lee, Yang Soon Kim, Joong-Yeol Park, Ki-Up Lee, Ghi Su Kim.   

Abstract

INTRODUCTION: High plasma homocysteine (Hcy) levels have been associated with increased risk of fracture. Since Hcy has been shown to induce apoptosis in many cell types, including vascular endothelial cells, we hypothesized that Hcy would have a similar apoptotic effect on osteoblasts, leading to osteoporosis by reducing bone formation.
MATERIALS AND METHODS: Using primary human bone marrow stromal cells (hBMSC) and HS-5 cell line (human bone marrow stromal cell line), we investigated the effects of Hcy on these cells by cell viability assay and analysis of cytoplasmic histone-associated DNA fragments. Caspase activity assay, Western blots, and electrophoresis mobility shift assay (EMSA) were performed to find the mechanism of apoptosis. Intracellular reactive oxygen species (ROS) were measured by spectrometry using dichlorofluorescein diacetate, and cellular total glutathione level was determined by a commercially available kit. N-acetylcysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) were used as tools for investigating the role of ROS and nuclear factor-kappaB (NF-kappaB), respectively.
RESULTS: Hcy induced apoptosis in primary human bone marrow stromal cells and the HS-5 cell line, and this apoptotic effect was caspase-dependent. In addition, Hcy increased cytochrome c release into the cytosol, and activated caspase-9 and caspase-3, but not caspase-8, indicating that Hcy induces apoptosis via the mitochondria pathway. Hcy increased ROS, and NAC inhibited the apoptotic effect of Hcy. Western blot and EMSA showed that Hcy activated the NF-kappaB pathway. PDTC blocked Hcy-induced caspase-3 activation and apoptosis.
CONCLUSION: These results suggest that Hcy induces apoptosis via the ROS-mediated mitochondrial pathway and NF-kappaB activation in hBMSCs, and that Hcy may contribute to the development of osteoporosis by reducing bone formation. Antioxidants may have a role in preventing bone loss in individuals with hyperhomocysteinemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644300     DOI: 10.1016/j.bone.2006.03.004

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  33 in total

Review 1.  B vitamins, homocysteine, and bone disease: epidemiology and pathophysiology.

Authors:  Robert R McLean; Marian T Hannan
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

2.  Global urinary metabolic profiling of the osteonecrosis of the femoral head based on UPLC-QTOF/MS.

Authors:  Gang Yang; Gang Zhao; Jian Zhang; Sichuan Gao; Tingmei Chen; Shijia Ding; Yun Zhu
Journal:  Metabolomics       Date:  2019-02-20       Impact factor: 4.290

Review 3.  Homocysteine imbalance: a pathological metabolic marker.

Authors:  Kevin L Schalinske; Anne L Smazal
Journal:  Adv Nutr       Date:  2012-11-01       Impact factor: 8.701

4.  Vitamin B12 protects against superoxide-induced cell injury in human aortic endothelial cells.

Authors:  Edward S Moreira; Nicola E Brasch; June Yun
Journal:  Free Radic Biol Med       Date:  2011-06-02       Impact factor: 7.376

5.  Hyperhomocysteinemia from trimethylation of hepatic phosphatidylethanolamine during cholesterol cholelithogenesis in inbred mice.

Authors:  Ji Zhang; Diane E Handy; Yufang Wang; Guylaine Bouchard; Jacob Selhub; Joseph Loscalzo; Martin C Carey
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

6.  Toll-like receptor 4 mutation suppresses hyperhomocysteinemia-induced hypertension.

Authors:  Anastasia Familtseva; Pankaj Chaturvedi; Anuradha Kalani; Nevena Jeremic; Naira Metreveli; George H Kunkel; Suresh C Tyagi
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-03       Impact factor: 4.249

Review 7.  Homocysteine as a Pathological Biomarker for Bone Disease.

Authors:  Jyotirmaya Behera; Jyoti Bala; Mohammed Nuru; Suresh C Tyagi; Neetu Tyagi
Journal:  J Cell Physiol       Date:  2017-04-12       Impact factor: 6.384

8.  Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women.

Authors:  Ilhan Bayhan; Dilek Uygur; Nil Ugurlu; Gulnur Ozaksit
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 9.  Mitochondrial epigenetics in bone remodeling during hyperhomocysteinemia.

Authors:  Anuradha Kalani; Pradip K Kamat; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Mol Cell Biochem       Date:  2014-06-18       Impact factor: 3.396

Review 10.  The role of homocysteine in bone remodeling.

Authors:  Thomas P Vacek; Anuradha Kalani; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Clin Chem Lab Med       Date:  2013-03-01       Impact factor: 3.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.